Trial Profile
A Phase 2 Open Label Study of CaBozantinib in Patients With Advanced or Unresectable Renal cEll cArcinoma Pretreated With One immunochecKPOint INhibiTor (Anti PD1/PDL1): the BREAKPOINT Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Dec 2022
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms BREAKPOINT; MeetUro-03
- 29 Nov 2022 Primary endpoint (progression free survival (PFS)) has been met according to Results published in the Tumori
- 29 Nov 2022 Results published in the Tumori
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology